Cargando…
Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
BACKGROUND: Colitis is one of the immune-related side effects of immunotherapy. Usually, such type of side effect was reported to develop within a few weeks of treatment initiation, our case started within a few days. CASE SUMMARY: We present a case of a 37-year-old gentleman with bright red loose s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340999/ https://www.ncbi.nlm.nih.gov/pubmed/32699584 http://dx.doi.org/10.4251/wjgo.v12.i6.699 |
_version_ | 1783555142013943808 |
---|---|
author | Abu Khalaf, Suha Albarrak, Abdulmajeed Yousef, Mohamad Tahan, Veysel |
author_facet | Abu Khalaf, Suha Albarrak, Abdulmajeed Yousef, Mohamad Tahan, Veysel |
author_sort | Abu Khalaf, Suha |
collection | PubMed |
description | BACKGROUND: Colitis is one of the immune-related side effects of immunotherapy. Usually, such type of side effect was reported to develop within a few weeks of treatment initiation, our case started within a few days. CASE SUMMARY: We present a case of a 37-year-old gentleman with bright red loose stools, abdominal pain, and tenesmus. A diagnosis of colitis was made based on endoscopic and histologic findings. Treatment was thereafter continued with oral steroids and discontinuation of the immunotherapy medications. Symptoms resolved after starting the treatment and the patient continued to be symptom-free on subsequent follow-up. The unique about this case report is that the patient developed bloody diarrhea within five days of the 1(st) immunotherapy cycle, and the patient was on combined ipilimumab and nivolumab. CONCLUSION: Immunotherapy related complications might occur within days from being on immunotherapy; we need more research to open the way for future pathological and clinical research to further understand the pathophysiology behind it. |
format | Online Article Text |
id | pubmed-7340999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-73409992020-07-21 Immune checkpoint inhibitors induced colitis, stay vigilant: A case report Abu Khalaf, Suha Albarrak, Abdulmajeed Yousef, Mohamad Tahan, Veysel World J Gastrointest Oncol Case Report BACKGROUND: Colitis is one of the immune-related side effects of immunotherapy. Usually, such type of side effect was reported to develop within a few weeks of treatment initiation, our case started within a few days. CASE SUMMARY: We present a case of a 37-year-old gentleman with bright red loose stools, abdominal pain, and tenesmus. A diagnosis of colitis was made based on endoscopic and histologic findings. Treatment was thereafter continued with oral steroids and discontinuation of the immunotherapy medications. Symptoms resolved after starting the treatment and the patient continued to be symptom-free on subsequent follow-up. The unique about this case report is that the patient developed bloody diarrhea within five days of the 1(st) immunotherapy cycle, and the patient was on combined ipilimumab and nivolumab. CONCLUSION: Immunotherapy related complications might occur within days from being on immunotherapy; we need more research to open the way for future pathological and clinical research to further understand the pathophysiology behind it. Baishideng Publishing Group Inc 2020-06-15 2020-06-15 /pmc/articles/PMC7340999/ /pubmed/32699584 http://dx.doi.org/10.4251/wjgo.v12.i6.699 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Abu Khalaf, Suha Albarrak, Abdulmajeed Yousef, Mohamad Tahan, Veysel Immune checkpoint inhibitors induced colitis, stay vigilant: A case report |
title | Immune checkpoint inhibitors induced colitis, stay vigilant: A case report |
title_full | Immune checkpoint inhibitors induced colitis, stay vigilant: A case report |
title_fullStr | Immune checkpoint inhibitors induced colitis, stay vigilant: A case report |
title_full_unstemmed | Immune checkpoint inhibitors induced colitis, stay vigilant: A case report |
title_short | Immune checkpoint inhibitors induced colitis, stay vigilant: A case report |
title_sort | immune checkpoint inhibitors induced colitis, stay vigilant: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340999/ https://www.ncbi.nlm.nih.gov/pubmed/32699584 http://dx.doi.org/10.4251/wjgo.v12.i6.699 |
work_keys_str_mv | AT abukhalafsuha immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport AT albarrakabdulmajeed immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport AT yousefmohamad immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport AT tahanveysel immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport |